Newcells Biotech is a pioneering company specialising in predictive human tissue models derived from induced pluripotent stem cells (iPSCs). Based in Newcastle upon Tyne, UK, the company develops advanced in vitro systems that replicate the structure and function of key human organs, including the retina, kidney, and lung. These models enable pharmaceutical and biotech companies to evaluate drug efficacy, safety, and toxicology with greater accuracy, reducing costs and accelerating development timelines.

Newcells Biotech is renowned for its kidney proximal tubule and retinal organoid models, widely used to predict nephrotoxicity and ocular toxicity in preclinical studies. Its proprietary platforms also support ADME (absorption, distribution, metabolism, and excretion) research, offering tailored solutions to enhance drug development. With a focus on innovation and collaboration, Newcells Biotech partners with global organisations to improve translational research, reduce reliance on animal models, and deliver safer, more effective therapies for patients.